Volume 16, Issue 3 (May & June 2025)                   BCN 2025, 16(3): 595-608 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Kazemi S, Hesni Langroudi N, Hasani Abharian P, Tavakol K, Taghi Joghataei M, Tavakol S et al . Short-term Efficacy of Commercial Curcumin Nanomicelle on Cognition, Oxidative Stress and Choline Esterase in Alzheimer’s Disease. BCN 2025; 16 (3) :595-608
URL: http://bcn.iums.ac.ir/article-1-2592-en.html
1- Department of Toxicology and Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran.
2- Department of Cognitive Rehabilitation, Brain and Cognition Clinic, Institute for Cognitive Science Studies, Tehran, Iran.
3- College of Medicine, Howard University, Washington DC, United States.
4- Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran. & Department of Anatomy, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
5- Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran. & Department of Research and Development, Tavakol BioMimetic Technologies Co, Tehran, Iran.
Abstract:  
Introduction: Alzheimer’s disease (AD) is a progressive neurodegenerative disease accompanied by cognitive dysfunction. Preclinical changes can precede the onset of clinical symptoms by decades, highlighting the need for preventative and therapeutic strategies to mitigate or delay disease progression. This pilot clinical trial aimed to investigate the effects of commercially available curcumin nanomicelles on oxidative stress pathways and serum cholinesterase levels in patients with AD.
Methods: Fifteen volunteers with mild-to-severe AD and 15 age-matched healthy controls were enrolled. Participants with AD received 80 mg of thermodynamically stable 10 nm curcumin nanomicelles on alternate days for two months. Cognitive function, as assessed by the mini-mental state examination (MMSE), did not exhibit significant changes in patients with AD following curcumin nanomicelle administration (19.8 versus 20.6). Serum levels of oxidative stress biomarkers, including catalase (CAT), superoxide dismutase (SOD) inhibition, malondialdehyde (MDA) concentration, and cholinesterase activity, were evaluated before and after intervention. 
Results: The results showed no significant differences in cognition improvement, CAT activity, SOD inhibition, MOD concentration, or cholinesterase activity between patients with AD and healthy controls or before and after curcumin nanomicelle administration. 
Conclusion: Although curcumin nanocarriers did not enhance antioxidant biomolecule levels, they did not provoke lipid peroxidation. Therefore, this study suggests that optimizing nanocarrier parameters, including concentration, particle size larger than 10 nm, and blood-brain barrier (BBB)targeting, warrants further investigation in a long-term study to explore their potential as supplemental therapies for AD.
Full-Text [PDF 1005 kb]   |   |   Full-Text (HTML)   
Type of Study: Original | Subject: Clinical Neuroscience
Received: 2022/11/8 | Accepted: 2024/09/7 | Published: 2025/05/29

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Basic and Clinical Neuroscience

Designed & Developed by : Yektaweb